id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-254580-nhpjvgt4	Ricardo, Jose W.	Considerations for Safety in the Use of Systemic Medications for Psoriasis and Atopic Dermatitis during the COVID‐19 pandemic	2020-05-27		.txt	text/plain	2758	144	38	In a pooled safety analysis of two randomized, controlled trials (RCTs) involving psoriasis patients treated with apremilast (n=1184), URIs and nasopharyngitis occurred in 19.2% and 16.6% of patients, respectively; serious infections (urinary tract infection n=2; appendicitis n=3; pneumonia=2) occurred in 1.4%. Anti-TNF-α therapies inhibit a crucial immunological pathway, therefore an immunosuppressive effect and increased infection risk are expected.	cache/cord-254580-nhpjvgt4.txt	txt/cord-254580-nhpjvgt4.txt
